EGFR and colorectal cancer: Although cetuximab-IRDye800CW has been investigated in other malignancies, its performance characteristics in colorectal cancer remain largely undefined—particularly the longitudinal stability of fluorescence signal, the relationship between signal intensity and EGFR expression, and the translational relevance for intraoperative decision-making.